DDIT3 and diffuse large B-cell lymphoma: Mechanisms of DLBCL progression following R-CHOP treatment in vivo are unclear, but we hypothesized that mutations enriched in R-CHOP-resistant patients versus newly diagnosed patients play a central role in relapse [9].